Phase 1-2 open-label, multiple-dose, dose-escalation study to evaluate the safety and tolerability of intravenous infusion of SNS01-T, a first-in-class modulator of eukaryotic translation initiation factor 5A (eIF5A) in patients (pts) with relapsed or refractory B-cell malignancies.
Michael Craig
No relevant relationships to disclose
William Bensinger
Research Funding - Senesco Technologies
David Samuel DiCapua Siegel
Consultant or Advisory Role - Celgene; Merck; Millennium; Onyx
Honoraria - Celgene; Merck; Millennium; Onyx
Frits Van Rhee
No relevant relationships to disclose
Nicolas Novitzky
No relevant relationships to disclose
Andrew Mcdonald
No relevant relationships to disclose
Martin Gutierrez
No relevant relationships to disclose
Edward N. Libby
No relevant relationships to disclose
John Thompson
Employment or Leadership Position - Senesco Technologies
Stock Ownership - Senesco Technologies
Alice Susannah Bexon
Consultant or Advisory Role - Senesco Technologies
Charles Barranco
Consultant or Advisory Role - Senesco Technologies
Catherine Taylor
Stock Ownership - Senesco Technologies
Richard Dondero
Employment or Leadership Position - Senesco Technologies
Stock Ownership - Senesco Technologies
Leslie J. Browne
Employment or Leadership Position - Senesco Technologies
Stock Ownership - Senesco Technologies
Michael R. Kurman
Consultant or Advisory Role - Senesco Technologies
John Anthony Lust
Consultant or Advisory Role - Senesco Technologies